Breaking Finance News

Global Medical REIT Inc (NASDAQ:GMRE) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Boasting a price of $7.32, Global Medical REIT Inc (NASDAQ:GMRE) traded -1.35% lower on the day. The last closing price is down -25.10% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. GMRE has recorded a 50-day average of $8.53 and a two hundred day average of $9.77. Volume of trade was down over the average, with 152,454 shares of GMRE changing hands under the typical 164,120

Zacks Investment Research has downgraded Global Medical REIT Inc (NASDAQ:GMRE) to Sell in a statement released on 11/28/2016.

Performance Chart

Global Medical REIT Inc (NASDAQ:GMRE)

With a total market value of $0, Global Medical REIT Inc has 52 week low of $6.73 and a 52 week high of $11.38 .

General Company Details For Global Medical REIT Inc (NASDAQ:GMRE)

Global Medical REIT Inc. focuses on operating as a real estate investment trust. The Company is engaged primarily in the acquisition and leasing of licensed purpose-built healthcare facilities in certain markets with various clinical operators. The Company seeks to invest in these purpose-built, specialized facilities, such as surgery centers, specialty hospitals and outpatient treatment centers. Its tenant-operators are physician group tenant-operators, community hospital tenant-operators and corporate medical treatment chain operators. Its properties include a six building, 52,266 square foot medical clinic portfolio in Tennessee; a combined approximately 27,190 square foot surgery center and medical office building located in West Mifflin, Pennsylvania; an approximately 8,840 square foot medical office building known as the Orthopedic Surgery Center, located in Asheville, North Carolina, and a 56-bed long term acute care hospital located at 1870 South 75th Street, Omaha, Nebraska.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.